Successful heart-lung complex transplantation was performed in a 48-year-old man. During the postoperative period, M. tuberculosis infection was diagnosed, and the treatment subsequently started. One year after, the patient was urgently hospitalized due to myocardial infarction. However, despite the best efforts, the patient died. Antituberculosis treatment is recommended to all the patients with confirmed active tuberculosis. Treatment of tuberculosis in transplant recipients is similar to that of the general population, with the exclusion of rifamycins in the regimen and longer duration of treatment.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Systemic pro-inflammatory response following bronchoscopic lung volume reduction using endobronchial valves.
ERJ Open Res
March 2025
University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases, Groningen, The Netherlands.
Rationale: Bronchoscopic lung volume reduction treatment using endobronchial valves (EBV) is an effective treatment for severe COPD patients by improving lung function and quality of life. However, little is known about its effects on systemic inflammation. Therefore, the aim of our study was to investigate whether EBV treatment impacts the inflammatory cytokine profile.
View Article and Find Full Text PDFRight heart failure and mortality in patients undergoing transcatheter tricuspid valve interventions.
Int J Cardiol
March 2025
HerzZentrum Hirslanden, Zurich, Switzerland.
Aims: To assess the association between right heart failure (RHF) and mortality in patients with severe tricuspid regurgitation (TR) undergoing transcatheter tricuspid valve intervention (TTVI), and to determine whether clinical RHF status reduces the survival benefit of successful versus failed TTVI.
Methods And Results: The TriValve International Registry (Transcatheter Tricuspid Valve Therapies) is a multicenter registry collecting data of patients with symptomatic, severe or greater TR undergoing TTVI. The population was stratified according to RHF status defined by the following clinical criteria: history of previous hospitalization for RHF (<1 year) OR presence of signs of RHF (jugular venous distension, ascites, peripheral oedema) OR high dose diuretic (≥125 mg/day of furosemide or equivalent).
Stereotactic body radiotherapy for treating lung cancer with a leadless pacemaker: A case report.
Medicine (Baltimore)
March 2025
Department of Radiology Division, Nara Prefecture General Medical Center, Nara, Japan.
Rationale: Stereotactic body radiotherapy (SBRT) is a precise treatment modality for lung cancer, delivering high-dose radiation to tumors while sparing surrounding organs. However, because of their intracardiac placement and proximity to the chest radiation field, leadless pacemakers (LLPMs) pose unique challenges that are not fully addressed by the existing protocols for conventional pacemakers.
Patient Concerns: In this case study, we aimed to emphasize the importance of identifying LLPMs before initiating SBRT for lung cancer and to discuss the necessary adjustments in treatment planning needed to accommodate these devices.
Comparison of usability and user-friendliness of three FeNO analyzers in a general population cohort of the LEAD study.
Sci Rep
March 2025
Ludwig Boltzmann Institute for Lung Health, Pavillon Hermann, 3rd Floor, Sanatoriumstreet 2, 1140, Vienna, Austria.
Exhaled nitric oxide (FeNO) is a marker for airway inflammation measured by hand-held or stationary analyzers, but their usability was not previously assessed. NIOX VERO (CN), NObreath (BN), Vivatmo pro (BV), and CLD88 analyzer (reference, EC) were compared in a prospective study of the general population LEAD (Lung, hEart, sociAl, boDy) cohort, including the System Usability Scale and tests for equivalence at a clinically relevant range of ≤ 70 ppb with linear models and Bland-Altman plots. In 486 participants (62.
View Article and Find Full Text PDFIntroducing the use of AngioVac in nonbacterial thrombotic endocarditis: a systematic review.
Future Cardiol
March 2025
Department of Medicine, Jacobi Medical Center/New York City Health and Hospitals Corporation, Bronx, NY, USA.
Introduction: Nonbacterial thrombotic endocarditis (NBTE) involves vegetations on heart valves without active bloodstream infection. The AngioVac device, a vacuum-based aspiration system commonly used for infective endocarditis, has potential in managing NBTE, particularly in patients unsuitable for surgery. This study systematically reviews the literature to evaluate AngioVac's effectiveness in reducing vegetations in NBTE.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!